Profile data is unavailable for this security.
About the company
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
- Revenue in JPY (TTM)522.00m
- Net income in JPY-5.39bn
- Incorporated2011
- Employees64.00
- LocationHealios KK11F, Seiroka Tower, 8-1, Akashi-choCHIYODA-KU 100-0006JapanJPN
- Phone+81 345908006
- Fax+81 335448760
- Websitehttps://www.healios.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OncoTherapy Science, Inc. | 562.70m | -1.19bn | 10.87bn | 54.00 | -- | 14.31 | -- | 19.31 | -5.39 | -5.39 | 2.55 | 2.80 | 0.4431 | 5.18 | 15.94 | 10,420,280.00 | -93.70 | -55.67 | -129.70 | -63.82 | -30.63 | -1.49 | -211.47 | -247.47 | 2.67 | -255.18 | 0.1146 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
| 3-D Matrix Ltd | 5.25bn | -1.05bn | 11.50bn | 106.00 | -- | 10.20 | -- | 2.19 | -12.89 | -12.89 | 66.88 | 11.66 | 0.8559 | 0.551 | 5.40 | 49,502,420.00 | -17.15 | -42.10 | -21.31 | -55.60 | 68.38 | 53.95 | -20.04 | -96.03 | 2.51 | -- | 0.7979 | -- | 98.30 | 69.41 | 89.55 | -- | -30.34 | -- |
| Tsubota Laboratory Inc | 674.29m | -691.35m | 11.69bn | 7.00 | -- | 9.80 | -- | 17.34 | -27.06 | -27.06 | 26.38 | 46.62 | 0.2974 | 1.83 | 465.35 | 96,327,430.00 | -30.50 | -- | -42.97 | -- | 7.89 | -- | -102.53 | -- | 2.20 | -434.24 | 0.085 | -- | -29.45 | -- | -811.14 | -- | -- | -- |
| Medinet Co Ltd | 759.11m | -1.34bn | 11.90bn | 98.00 | -- | 2.22 | -- | 15.68 | -5.53 | -5.53 | 3.10 | 20.31 | 0.1347 | 11.64 | 3.73 | 7,745,980.00 | -23.85 | -21.05 | -24.99 | -22.47 | 17.78 | 28.75 | -177.09 | -135.40 | 18.90 | -- | 0.00 | -- | 4.40 | -7.90 | -14.66 | -- | -17.67 | -- |
| Nano Mrna Co Ltd | 76.60m | -650.31m | 13.77bn | 18.00 | -- | 4.21 | -- | 179.79 | -9.24 | -9.24 | 1.09 | 46.27 | 0.0145 | 24.08 | 1.45 | 4,255,556.00 | -12.33 | -24.16 | -13.57 | -25.17 | 78.30 | 84.69 | -848.97 | -600.70 | 9.24 | -- | 0.2540 | -- | -32.98 | -22.88 | 40.50 | -- | -- | -- |
| PRISM BioLab Co Ltd | -100.00bn | -100.00bn | 16.72bn | 22.00 | -- | 7.01 | -- | -- | -- | -- | -- | 66.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -79.63 | -- | -822.18 | -- | -- | -- |
| AnGes Inc | 449.34m | -6.11bn | 19.14bn | 145.00 | -- | 0.7267 | -- | 42.59 | -29.92 | -29.92 | 2.22 | 107.33 | 0.0139 | 0.1931 | 4.02 | 3,098,862.00 | -18.95 | -28.50 | -22.32 | -33.14 | 38.79 | 39.42 | -1,359.35 | -6,726.82 | 1.19 | -- | 0.013 | -- | 128.13 | -24.17 | 49.45 | -- | 12.11 | -- |
| Healios KK | 522.00m | -5.39bn | 21.72bn | 64.00 | -- | 6.69 | -- | 41.61 | -68.16 | -68.16 | 6.56 | 36.00 | 0.0321 | -- | 1.61 | 8,156,250.00 | -33.11 | -23.55 | -49.17 | -28.52 | 85.06 | -- | -1,030.65 | -6,580.16 | -- | -1.49 | 0.7469 | -- | 34.44 | -- | 26.04 | -- | -22.00 | -- |
| Pharma Foods International Co., Ltd. | 62.15bn | 3.21bn | 25.62bn | 670.00 | 7.76 | 2.13 | 6.23 | 0.4122 | 113.47 | 113.47 | 2,185.12 | 412.69 | 1.71 | 2.10 | 14.00 | -- | 8.81 | 8.63 | 25.38 | 22.06 | 78.45 | 80.64 | 5.16 | 4.13 | 0.8875 | 81.16 | 0.5932 | 26.28 | -9.37 | 42.62 | 4.02 | 45.01 | 28.23 | -- |
| Chordia Therapeutics Inc | -100.00bn | -100.00bn | 28.88bn | 21.00 | -- | 7.27 | -- | -- | -- | -- | -- | 58.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 112.55 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Healios KK's reporting currency: Japanese Yen JPY
22.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Athos Capital Ltd.as of 09 Feb 2024 | 13.50m | 14.98% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 2.49m | 2.77% |
| Oasis Management (Hong Kong) LLCas of 09 Feb 2024 | 1.04m | 1.16% |
| Mirabella Financial Services LLPas of 09 Feb 2024 | 1.04m | 1.16% |
| Heights Capital Management, Inc.as of 02 Feb 2024 | 640.10k | 0.71% |
| Panview Capital Ltd.as of 09 Aug 2023 | 543.40k | 0.60% |
| Maven Investment Partners Ltd.as of 12 Oct 2023 | 413.70k | 0.46% |
| Meiji Yasuda Asset Management Co. Ltd.as of 22 May 2023 | 372.20k | 0.41% |
| Simplex Asset Management Co., Ltd.as of 05 Sep 2024 | 242.30k | 0.27% |
| Rheos Capital Works, Inc. (Investment Management)as of 30 Sep 2022 | 162.60k | 0.18% |
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
